Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

weekly audio roundup of selected major global biopharma insights

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: Pfizer Inc.’s game-changing COVID oral antiviral results; Novartis AG sells Roche Holding AG stake; Novartis trumps productive pipeline; Bayer AG sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir" - Scrip, 5 Nov, 2021.)

 

(Also see "A Win-Win As Novartis Sells Roche Stake" - Scrip, 4 Nov, 2021.)

(Also see "Tsai Trumpets Productivity of Novartis Pipeline" - Scrip, 10 Nov, 2021.)

(Also see "Bayer Backs Hot Flashes Drug For Blockbuster Status" - Scrip, 9 Nov, 2021.)

(Also see "Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It" - Scrip, 11 Nov, 2021.)

Open Media